POSA162 Modeling the Ex Ante Real Option Value in a Highly Innovative Therapeutic Area: ALK-Positive Non-Small Cell Lung Cancer
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.303
https://www.valueinhealthjournal.com/article/S1098-3015(21)02098-2/fulltext
Title :
POSA162 Modeling the Ex Ante Real Option Value in a Highly Innovative Therapeutic Area: ALK-Positive Non-Small Cell Lung Cancer
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02098-2&doi=10.1016/j.jval.2021.11.303
First page :
Section Title :
Open access? :
No
Section Order :
11078